BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10917135)

  • 1. Evaluation of circulating activin-A as a serum marker of hepatocellular carcinoma.
    Pirisi M; Fabris C; Luisi S; Santuz M; Toniutto P; Vitulli D; Federico E; Del Forno M; Mattiuzzo M; Branca B; Petraglia F
    Cancer Detect Prev; 2000; 24(2):150-5. PubMed ID: 10917135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined serum hepatoma-specific alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma.
    Wu W; Yao DF; Yuan YM; Fan JW; Lu XF; Li XH; Qiu LW; Zong L; Wu XH
    Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):538-44. PubMed ID: 17085339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
    Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
    Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevation of serum type IV collagen in liver cancer as well as liver cirrhosis.
    Hong WS; Hong SI; Park SY; Son Y; Lee YS; Chung YH; Yang SK; Suh DJ; Min YI
    Anticancer Res; 1995; 15(6B):2777-80. PubMed ID: 8669863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma.
    Lee MJ; Yu GR; Park SH; Cho BH; Ahn JS; Park HJ; Song EY; Kim DG
    Clin Cancer Res; 2008 Feb; 14(4):1080-9. PubMed ID: 18281540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
    Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
    Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible contribution of serum activin A and IGF-1 in the development of hepatocellular carcinoma in Egyptian patients suffering from combined hepatitis C virus infection and hepatic schistosomiasis.
    Elsammak MY; Amin GM; Khalil GM; Ragab WS; Abaza MM
    Clin Biochem; 2006 Jun; 39(6):623-9. PubMed ID: 16624274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study.
    Mazziotti G; Sorvillo F; Morisco F; Carbone A; Rotondi M; Stornaiuolo G; Precone DF; Cioffi M; Gaeta GB; Caporaso N; Carella C
    Cancer; 2002 Dec; 95(12):2539-45. PubMed ID: 12467068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma.
    Beneduce L; Castaldi F; Marino M; Quarta S; Ruvoletto M; Benvegnù L; Calabrese F; Gatta A; Pontisso P; Fassina G
    Cancer; 2005 Jun; 103(12):2558-65. PubMed ID: 15887222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma.
    Soresi M; Magliarisi C; Campagna P; Leto G; Bonfissuto G; Riili A; Carroccio A; Sesti R; Tripi S; Montalto G
    Anticancer Res; 2003; 23(2C):1747-53. PubMed ID: 12820452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of alpha-fetoprotein mRNA in blood of patients with hepatocellular carcinoma.
    Cillo U; Navaglia F; Vitale A; Molari A; Basso D; Bassanello M; Brolese A; Zanus G; Montin U; D'Amico F; Ciarleglio FA; Carraro A; Bridda A; Burra P; Carraro P; Plebani M; D'Amico DF
    Clin Chim Acta; 2004 Sep; 347(1-2):129-38. PubMed ID: 15313150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of serum protective activity against acid precipitation of poly (U) in the differentiation between cirrhotic patients with and without hepatocellular carcinoma.
    Kouretas D; Kountouras J; Tsapas G; Anastasiades N; Tsakiri I; Antonoglou O
    Anticancer Res; 1990; 10(4):1025-8. PubMed ID: 1696444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis.
    Henry L; Lavabre-Bertrand T; Vercambre L; Ramos J; Carillo S; Guiraud I; Pouderoux P; Bismuth M; Valats JC; Demattei C; Duny Y; Chaze I; Funakoshi N; Bureau JP; Daurès JP; Blanc P
    Gut; 2009 Jun; 58(6):833-8. PubMed ID: 19201777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma.
    Beneduce L; Pesce G; Gallotta A; Zampieri F; Biasiolo A; Tono N; Boscato N; Gatta A; Pontisso P; Fassina G
    Eur J Clin Invest; 2008 Aug; 38(8):571-7. PubMed ID: 18625005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.
    Kemmer N; Neff G; Kaiser T; Zacharias V; Thomas M; Tevar A; Satwah S; Shukla R; Buell J
    Liver Transpl; 2006 Oct; 12(10):1519-22. PubMed ID: 17004260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma.
    Scholz A; Rehm VA; Rieke S; Derkow K; Schulz P; Neumann K; Koch I; Pascu M; Wiedenmann B; Berg T; Schott E
    Am J Gastroenterol; 2007 Nov; 102(11):2471-81. PubMed ID: 17581268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical value of serum ferritin in hepatocellular carcinoma.
    Simonetti RG; Craxi A; Dardanonì G; Lanzarone F; Barbaria F; Cottone M; Pagliaro L
    Hepatogastroenterology; 1985 Dec; 32(6):276-8. PubMed ID: 2419233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma.
    Miura N; Maeda Y; Kanbe T; Yazama H; Takeda Y; Sato R; Tsukamoto T; Sato E; Marumoto A; Harada T; Sano A; Kishimoto Y; Hirooka Y; Murawaki Y; Hasegawa J; Shiota G
    Clin Cancer Res; 2005 May; 11(9):3205-9. PubMed ID: 15867214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.